Top Markets
#1 Siren Siren +35.55%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.06%
#3 PulseChain PulseChain +17.72%
#4 Ribbita by Virtuals Ribbita by Virtuals +17.03%
#5 OpenEden OpenEden +16.58%
#6 Cysic Cysic +16.56%
#7 BasedHype BasedHype +15.88%
#8 The Grays Currency The Grays Currency +15.71%
#9 KUB Coin KUB Coin +15.65%
#10 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +15.50%
Coin of the day
Siren Siren
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Celyad Oncology S.A. Celyad Oncology S.A.

Celyad Oncology S.A.

CYAD
Classement en actions #30831
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Prix de l'action
$0.343985
Capitalisation boursière
$15.40M
Changement (1 jour)
3.94%
Changement (1 an)
-25.19%
Pays
BE
Échange Celyad Oncology S.A. (CYAD)

Catégorie

Healthcare
Le prix CYAD avec la capitalisation boursière de B
Celyad Oncology S.A. Celyad Oncology S.A.
CYAD
$0.343985
Capitalisation boursière de Celyad Oncology S.A.(CYAD)
Capitalisation boursière: $15.40M
En August 2026, Celyad Oncology S.A. a une capitalisation boursière de $15.40M. Cela fait de Celyad Oncology S.A. la 30831st entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Celyad Oncology S.A. du 2013 au 2026
CYAD par rapport au top 5 des plus populaires stocks
Prix pour CYAD L’actif B La capitalisation boursière de B Résultats
Celyad Oncology S.A. Celyad Oncology S.A.
$118,933 $15.40M
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.324T +34,575,028.85%
Celyad Oncology S.A. Celyad Oncology S.A.
$101,898 $15.40M
Apple Inc. Apple Inc.
AAPL
$4.561T +29,622,577.56%
Celyad Oncology S.A. Celyad Oncology S.A.
$92,509.30 $15.40M
Alphabet Inc. Alphabet Inc.
GOOG
$4.141T +26,893,312.18%
Celyad Oncology S.A. Celyad Oncology S.A.
$79,930.75 $15.40M
Microsoft Corporation Microsoft Corporation
MSFT
$3.578T +23,236,597.51%
Celyad Oncology S.A. Celyad Oncology S.A.
$62,909.30 $15.40M
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.816T +18,288,283.37%